{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:15:52Z","timestamp":1794550552764,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["RFS2223\/0621\/23"],"award-info":[{"award-number":["RFS2223\/0621\/23"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003452","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","award":["MRP 029\/21"],"award-info":[{"award-number":["MRP 029\/21"]}],"id":[{"id":"10.13039\/501100003452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"DOI":"10.1038\/s42255-025-01336-4","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T09:03:49Z","timestamp":1753952629000},"page":"1614-1629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combining a diet rich in fermentable carbohydrates with metformin improves glycaemic control and reshapes the gut microbiota in people with prediabetes"],"prefix":"10.1038","volume":"7","author":[{"given":"Natural H. S.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily W. M.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3434-1326","authenticated-orcid":false,"given":"Jimmy Y. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1194","authenticated-orcid":false,"given":"Juliana C. N.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-3387","authenticated-orcid":false,"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee 3. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes\u20142024. Diabetes Care 47, S43\u2013S51 (2024).","DOI":"10.2337\/dc24-S003"},{"key":"1336_CR2","doi-asserted-by":"publisher","first-page":"e00009","DOI":"10.1002\/edm2.9","volume":"1","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Gut microbiome differences between metformin\u2010 and liraglutide\u2010treated T2DM subjects. Endocrinol. Diabetes Metab. 1, e00009 (2018).","journal-title":"Endocrinol. Diabetes Metab."},{"key":"1336_CR3","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.bbadis.2019.04.009","volume":"1865","author":"R Tian","year":"2019","unstructured":"Tian, R. et al. Metformin ameliorates endotoxemia-induced endothelial pro-inflammatory responses via AMPK-dependent mediation of HDAC5 and KLF2. Biochim. Biophys. Acta 1865, 1701\u20131712 (2019).","journal-title":"Biochim. Biophys. Acta"},{"key":"1336_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55\u201360 (2012).","journal-title":"Nature"},{"key":"1336_CR5","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/s41591-024-03067-7","volume":"30","author":"Z Mei","year":"2024","unstructured":"Mei, Z. et al. Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes. Nat. Med. 30, 2265\u20132276 (2024).","journal-title":"Nat. Med."},{"key":"1336_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","volume":"63","author":"N-R Shin","year":"2014","unstructured":"Shin, N.-R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727\u2013735 (2014).","journal-title":"Gut"},{"key":"1336_CR7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/dc20-2257","volume":"44","author":"NT Mueller","year":"2021","unstructured":"Mueller, N. T. et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: a randomized trial. Diabetes Care 44, 1462\u20131471 (2021).","journal-title":"Diabetes Care"},{"key":"1336_CR8","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1210\/jc.2017-01091","volume":"102","author":"A Br\u00f8nden","year":"2017","unstructured":"Br\u00f8nden, A. et al. Single-dose metformin enhances bile acid-induced glucagon-like peptide-1 secretion in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 102, 4153\u20134162 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1336_CR9","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/db22-0168","volume":"71","author":"J Cui","year":"2022","unstructured":"Cui, J. et al. Butyrate-producing bacteria and insulin homeostasis: the Microbiome and Insulin Longitudinal Evaluation Study (MILES). Diabetes 71, 2438\u20132446 (2022).","journal-title":"Diabetes"},{"key":"1336_CR10","doi-asserted-by":"publisher","first-page":"e93936","DOI":"10.1172\/jci.insight.93936","volume":"3","author":"E Bahne","year":"2018","unstructured":"Bahne, E. et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight 3, e93936 (2018).","journal-title":"JCI Insight"},{"key":"1336_CR11","doi-asserted-by":"crossref","unstructured":"Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35, 731\u2013737 (2012).","DOI":"10.2337\/dc11-1299"},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S2213-8587(23)00132-8","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 11, 567\u2013577 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1336_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s00125-019-4848-7","volume":"62","author":"T Bryrup","year":"2019","unstructured":"Bryrup, T. et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia 62, 1024\u20131035 (2019).","journal-title":"Diabetologia"},{"key":"1336_CR14","doi-asserted-by":"publisher","first-page":"112448","DOI":"10.1016\/j.biopha.2021.112448","volume":"145","author":"CM D\u00edaz-Perdigones","year":"2022","unstructured":"D\u00edaz-Perdigones, C. M., Mu\u00f1oz-Garach, A., \u00c1lvarez-Berm\u00fadez, M. D., Moreno-Indias, I. & Tinahones, F. J. Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients. Biomed. Pharmacother. 145, 112448 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1336_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jgh.13685","volume":"32","author":"PR Gibson","year":"2017","unstructured":"Gibson, P. R. History of the low FODMAP diet. J. Gastroenterol. Hepatol. 32, 5\u20137 (2017).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1336_CR16","doi-asserted-by":"crossref","unstructured":"Vandeputte, D. & Joossens, M. Effects of low and high FODMAP diets on human gastrointestinal microbiota composition in adults with intestinal diseases: a systematic review. Microorganisms 8, 1638 (2020).","DOI":"10.3390\/microorganisms8111638"},{"key":"1336_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","volume":"146","author":"EP Halmos","year":"2014","unstructured":"Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R. & Muir, J. G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146, 67\u201375 (2014).","journal-title":"Gastroenterology"},{"key":"1336_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/j.1440-1746.2010.06370.x","volume":"25","author":"DK Ong","year":"2010","unstructured":"Ong, D. K. et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J. Gastroenterol. Hepatol. 25, 1366\u20131373 (2010).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1336_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2468-1253(24)00045-1","volume":"9","author":"S Nybacka","year":"2024","unstructured":"Nybacka, S. et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 507\u2013520 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1336_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/gutjnl-2021-325214","volume":"71","author":"CJ Black","year":"2022","unstructured":"Black, C. J., Staudacher, H. M. & Ford, A. C. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut 71, 1117\u20131126 (2022).","journal-title":"Gut"},{"key":"1336_CR21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/gutjnl-2015-311339","volume":"66","author":"K McIntosh","year":"2017","unstructured":"McIntosh, K. et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut 66, 1241\u20131251 (2017).","journal-title":"Gut"},{"key":"1336_CR22","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.3390\/nu15245070","volume":"15","author":"NH Chu","year":"2023","unstructured":"Chu, N. H. et al. Higher short-chain fermentable carbohydrates are associated with lower body fat and higher insulin sensitivity in people with prediabetes. Nutrients 15, 5070 (2023).","journal-title":"Nutrients"},{"key":"1336_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/1932296815577425","volume":"9","author":"JH Burton","year":"2015","unstructured":"Burton, J. H. et al. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J. Diabetes Sci. Technol. 9, 808\u2013814 (2015).","journal-title":"J. Diabetes Sci. Technol."},{"key":"1336_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/apt.13286","volume":"42","author":"BP Chumpitazi","year":"2015","unstructured":"Chumpitazi, B. P. et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment. Pharmacol. Ther. 42, 418\u2013427 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1336_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00125-016-3992-6","volume":"59","author":"RA DeFronzo","year":"2016","unstructured":"DeFronzo, R. A. et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 59, 1645\u20131654 (2016).","journal-title":"Diabetologia"},{"key":"1336_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2337\/dc15-0488","volume":"39","author":"JB Buse","year":"2016","unstructured":"Buse, J. B. et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39, 198\u2013205 (2016).","journal-title":"Diabetes Care"},{"key":"1336_CR27","doi-asserted-by":"publisher","first-page":"857090","DOI":"10.3389\/fendo.2022.857090","volume":"13","author":"N Chu","year":"2022","unstructured":"Chu, N., Chan, J. C. & Chow, E. Pharmacomicrobiomics in western medicine and traditional Chinese medicine in type 2 diabetes. Front. Endocrinol. 13, 857090 (2022).","journal-title":"Front. Endocrinol."},{"key":"1336_CR28","doi-asserted-by":"publisher","first-page":"1149256","DOI":"10.3389\/fendo.2023.1149256","volume":"14","author":"L Jia","year":"2023","unstructured":"Jia, L. & Zhu, C. Pharmacomicrobiomics and type 2 diabetes mellitus: a novel perspective towards possible treatment. Front. Endocrinol. 14, 1149256 (2023).","journal-title":"Front. Endocrinol."},{"key":"1336_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/gutjnl-2014-307264","volume":"64","author":"EP Halmos","year":"2015","unstructured":"Halmos, E. P. et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64, 93\u2013100 (2015).","journal-title":"Gut"},{"key":"1336_CR30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1053\/j.gastro.2017.06.010","volume":"153","author":"HM Staudacher","year":"2017","unstructured":"Staudacher, H. M. et al. A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores Bifidobacterium species: a randomized controlled trial. Gastroenterology 153, 936\u2013947 (2017).","journal-title":"Gastroenterology"},{"key":"1336_CR31","doi-asserted-by":"crossref","unstructured":"Chu, N., Chan, J. C. & Chow, E. A diet high in FODMAPs as a novel dietary strategy in diabetes? Clin. Nutr. 41, 2103\u20132112 (2022).","DOI":"10.1016\/j.clnu.2022.07.036"},{"key":"1336_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.858192","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee, H. et al. A novel bacterium, Butyricimonas virosa, preventing HFD-induced diabetes and metabolic disorders in mice via GLP-1 receptor. Front. Microbiol. 13, 858192 (2022).","journal-title":"Front. Microbiol."},{"key":"1336_CR33","doi-asserted-by":"publisher","first-page":"814770","DOI":"10.3389\/fendo.2021.814770","volume":"12","author":"C-Y Tsai","year":"2022","unstructured":"Tsai, C.-Y. et al. Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study. Front. Endocrinol. 12, 814770 (2022).","journal-title":"Front. Endocrinol."},{"key":"1336_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00125-019-05045-y","volume":"63","author":"H Ellingsgaard","year":"2020","unstructured":"Ellingsgaard, H. et al. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia 63, 362\u2013373 (2020).","journal-title":"Diabetologia"},{"key":"1336_CR35","doi-asserted-by":"publisher","first-page":"5110276","DOI":"10.1155\/2021\/5110276","volume":"2021","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications. Mediators Inflamm. 2021, 5110276 (2021).","journal-title":"Mediators Inflamm."},{"key":"1336_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-\u03b2-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225\u2013235 (2013).","journal-title":"Cell Metab."},{"key":"1336_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.trsl.2012.10.007","volume":"161","author":"BT Layden","year":"2013","unstructured":"Layden, B. T., Angueira, A. R., Brodsky, M., Durai, V. & Lowe, W. L. Jr Short chain fatty acids and their receptors: new metabolic targets. Transl. Res. 161, 131\u2013140 (2013).","journal-title":"Transl. Res."},{"key":"1336_CR38","doi-asserted-by":"publisher","first-page":"1087703","DOI":"10.3389\/fnut.2023.1087703","volume":"10","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Pediococcus pentosaceus PR-1 modulates high-fat-died-induced alterations in gut microbiota, inflammation, and lipid metabolism in zebrafish. Front. Nutr. 10, 1087703 (2023).","journal-title":"Front. Nutr."},{"key":"1336_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-019-0092-7","volume":"5","author":"C Zhao","year":"2019","unstructured":"Zhao, C., Dong, H., Zhang, Y. & Li, Y. Discovery of potential genes contributing to the biosynthesis of short-chain fatty acids and lactate in gut microbiota from systematic investigation in E. coli. NPJ Biofilms Microbiomes 5, 19 (2019).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"1336_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1320992","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Causal effects of gut microbiota on appendicitis: a two-sample Mendelian randomization study. Front. Cell. Infect. Microbiol. 13, 1320992 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1336_CR41","doi-asserted-by":"publisher","first-page":"490842","DOI":"10.1155\/2015\/490842","volume":"2015","author":"R Adela","year":"2015","unstructured":"Adela, R. & Banerjee, S. K. GDF\u201015 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res. 2015, 490842 (2015).","journal-title":"J. Diabetes Res."},{"key":"1336_CR42","doi-asserted-by":"crossref","unstructured":"Xiao, S. et al. Lac-Phe mediates the effects of metformin on food intake and body weight. Nat. Metab. 6, 659\u2013669 (2024).","DOI":"10.1038\/s42255-024-00999-9"},{"key":"1336_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/jpbs.JPBS_370_20","volume":"13","author":"SW Gillani","year":"2021","unstructured":"Gillani, S. W., Ghayedi, N., Roosta, P., Seddigh, P. & Nasiri, O. Effect of metformin on lipid profiles of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J. Pharm. Bioallied Sci. 13, 76\u201382 (2021).","journal-title":"J. Pharm. Bioallied Sci."},{"key":"1336_CR44","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00394-019-02104-3","volume":"59","author":"Y-J Kwon","year":"2020","unstructured":"Kwon, Y.-J., Lee, H. S., Chang, H.-J., Koh, S.-B. & Lee, J.-W. Association of dietary lipid intake with low-density lipoprotein cholesterol levels: analysis of two independent population-based studies. Eur. J. Nutr. 59, 2557\u20132567 (2020).","journal-title":"Eur. J. Nutr."},{"key":"1336_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/biology13070498","volume":"13","author":"NH Chu","year":"2024","unstructured":"Chu, N. H., Chow, E. & Chan, J. C. The therapeutic potential of the specific intestinal microbiome (SIM) diet on metabolic diseases. Biology 13, 498 (2024).","journal-title":"Biology"},{"key":"1336_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12902-018-0288-5","volume":"18","author":"AOY Luk","year":"2018","unstructured":"Luk, A. O. Y. et al. A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetes. BMC Endocr. Disord. 18, 59 (2018).","journal-title":"BMC Endocr. Disord."},{"key":"1336_CR47","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2015.11.001","volume":"163","author":"D Zeevi","year":"2015","unstructured":"Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079\u20131094 (2015).","journal-title":"Cell"},{"key":"1336_CR48","doi-asserted-by":"crossref","unstructured":"Zahalka, S. J., Galindo, R. J., Shah, V. N. & Low Wang, C. C. Continuous glucose monitoring for prediabetes: what are the best metrics? J. Diabetes Sci. Technol. 18, 835\u2013846 (2024).","DOI":"10.1177\/19322968241242487"},{"key":"1336_CR49","doi-asserted-by":"publisher","unstructured":"Chow, E. et al. 1827-P: higher glucagon-like peptide-1 response and lower beta-cell glucose sensitivity are associated with increased glycemic variability among individuals with prediabetes. Diabetes https:\/\/doi.org\/10.2337\/db19-1827-P (2019).","DOI":"10.2337\/db19-1827-P"},{"key":"1336_CR50","doi-asserted-by":"crossref","unstructured":"Spartano, N. L. et al. Defining continuous glucose monitor time in range in a large, community-based cohort without diabetes. J. Clin. Endocrinol. Metab. 110, 1128\u20131134 (2024).","DOI":"10.1210\/clinem\/dgae626"},{"key":"1336_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/dia.2022.0271","volume":"25","author":"B Guerci","year":"2023","unstructured":"Guerci, B. et al. Important decrease in hospitalizations for acute diabetes events following freestyle libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol. Ther. 25, 20\u201330 (2023).","journal-title":"Diabetes Technol. Ther."},{"key":"1336_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2019.09.024","volume":"158","author":"SR Cox","year":"2020","unstructured":"Cox, S. R. et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology 158, 176\u2013188 (2020).","journal-title":"Gastroenterology"},{"key":"1336_CR53","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3920\/BM2016.0230","volume":"8","author":"M Gonai","year":"2017","unstructured":"Gonai, M. et al. Galacto-oligosaccharides ameliorate dysbiotic Bifidobacteriaceae decline in Japanese patients with type 2 diabetes. Benef. Microbes 8, 705\u2013716 (2017).","journal-title":"Benef. Microbes"},{"key":"1336_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/j.gastro.2017.03.051","volume":"153","author":"EE Canfora","year":"2017","unstructured":"Canfora, E. E. et al. Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 153, 87\u201397 (2017).","journal-title":"Gastroenterology"},{"key":"1336_CR55","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2036.2011.04594.x","volume":"33","author":"A Attaluri","year":"2011","unstructured":"Attaluri, A., Donahoe, R., Valestin, J., Brown, K. & Rao, S. S. C. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment. Pharmacol. Ther. 33, 822\u2013828 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1336_CR56","doi-asserted-by":"publisher","DOI":"10.1017\/jns.2019.14","volume":"8","author":"SL Eady","year":"2019","unstructured":"Eady, S. L. et al. The effect of \u2018Zesy002\u2019 kiwifruit (Actinidia chinensis var. chinensis) on gut health function: a randomised cross-over clinical trial. J. Nutr. Sci. 8, e18 (2019).","journal-title":"J. Nutr. Sci."},{"key":"1336_CR57","first-page":"G361","volume":"318","author":"M M\u00fcller","year":"2020","unstructured":"M\u00fcller, M. et al. Distal colonic transit is linked to gut microbiota diversity and microbial fermentation in humans with slow colonic transit. Am. J. Physiol. 318, G361\u2013G369 (2020).","journal-title":"Am. J. Physiol."},{"key":"1336_CR58","unstructured":"World Health Organization (ed.) Waist Circumference and Waist\u2013Hip Ratio: Report of a WHO Expert Consultation (World Health Organization, 2008)."},{"key":"1336_CR59","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa2007123","volume":"384","author":"DJ Jenkins","year":"2021","unstructured":"Jenkins, D. J. et al. Glycemic index, glycemic load, and cardiovascular disease and mortality. N. Engl. J. Med. 384, 1312\u20131322 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR60","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2337\/diacare.20.4.545","volume":"20","author":"J Salmer\u00f3n","year":"1997","unstructured":"Salmer\u00f3n, J. et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 20, 545\u2013550 (1997).","journal-title":"Diabetes Care"},{"key":"1336_CR61","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1021\/jf802700e","volume":"57","author":"JG Muir","year":"2009","unstructured":"Muir, J. G. et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). J. Agric. Food Chem. 57, 554\u2013565 (2009).","journal-title":"J. Agric. Food Chem."},{"key":"1336_CR62","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1079\/PHN2005898","volume":"9","author":"M Hagstr\u00f6mer","year":"2006","unstructured":"Hagstr\u00f6mer, M., Oja, P. & Sj\u00f6str\u00f6m, M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 9, 755\u2013762 (2006).","journal-title":"Public Health Nutr."},{"key":"1336_CR63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino, T. et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 11, 42\u201357 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1336_CR64","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00592-018-1140-0","volume":"55","author":"K Pagacz","year":"2018","unstructured":"Pagacz, K., Stawiski, K., Szadkowska, A., Mlynarski, W. & Fendler, W. GlyCulator2: an update on a web application for calculation of glycemic variability indices. Acta Diabetol. 55, 877\u2013880 (2018).","journal-title":"Acta Diabetol."},{"key":"1336_CR65","first-page":"185","volume":"30","author":"ETP Lam","year":"2008","unstructured":"Lam, E. T. P., Lam, C. L. K., Lo, Y. Y. C. & Gandek, B. Psychometrics and population norm of the Chinese (HK) SF-36 Health Survey_Version 2. Hong Kong Pract. 30, 185\u2013198 (2008).","journal-title":"Hong Kong Pract."},{"key":"1336_CR66","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462\u20131470 (1999).","journal-title":"Diabetes Care"},{"key":"1336_CR67","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00125-003-1169-6","volume":"46","author":"E Ferrannini","year":"2003","unstructured":"Ferrannini, E. et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 46, 1211\u20131219 (2003).","journal-title":"Diabetologia"},{"key":"1336_CR68","unstructured":"Chow, E. et al. A randomized controlled trial of intermittently-scanned continuous glucose monitoring as an adjunct to lifestyle modification in impaired glucose tolerance. Diabetologia 66, 22 (2023)."},{"key":"1336_CR69","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2013)."},{"key":"1336_CR70","doi-asserted-by":"publisher","unstructured":"Chu, N. FODMAPs and metformin study. figshare https:\/\/doi.org\/10.6084\/m9.figshare.28123295.v1 (2025).","DOI":"10.6084\/m9.figshare.28123295.v1"}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01336-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:59:54Z","timestamp":1757293194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01336-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1038\/s42255-025-01336-4","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C. has received speaker honoraria from AstraZeneca, Procter & Gamble and ZP Therapeutics and institutional research support from Merck KGaA, Hua Medicine, Medtronic Diabetes, Powder Pharmaceuticals and Sanofi. J.C.N.C. has received research grants and\/or honoraria for consultancy or giving lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Hua Medicine, Lee Powder, Merck Serono, Merck Sharp & Dohme, Pfizer, Servier, Sanofi and Viatris Pharmaceutical. Monash University financially benefits from the sales of digital applications and booklets associated with the low-FODMAP diet. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}